JNK3 as a Therapeutic Target for Neurodegenerative Diseases
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
c-Jun N-terminal kinases (JNKs) and in particular JNK3 the neuronal specific isoform, have been recognized as important enzymes in the pathology of diverse neurological disorders. Indeed, several efforts have been made to design drugs that inhibit JNK signaling. The success that characterized the new generation of cell permeable peptides raise the hope in the field of neurodegeneration for new therapeutic routes. However, in order to design new and more efficient therapeutical approaches careful re-examination of current knowledge is required. Scaffold proteins are key endogenous regulators of JNK signaling: they can modulate spatial and temporal activation of the JNK signaling and can thus provide the basis for the design of more specific inhibitors. This review focuses on delineating the role of scaffold proteins on the regulation of JNK signaling in neurons. Furthermore the possibility to design a new JNK3 cell permeable peptide inhibitor by targeting the β-arrestin-JNK3 interaction is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237 · cited 2×
“In fact until now it is very difficult to discriminate against the 10 different isoforms of the JNK family, which are formed by alternate slicing of the three genes, Jnk1, Jnk2, Jnk3 [1].”
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · cited 1×
“JNK3 is mainly modulated by CNS stress stimuli while JNK1 and 2 are more implicated in insulin resistance, autoimmune or inflammatory diseases and cancer [16, 18, 20, 72–77].”
A Cytoplasmic Inhibitor of the JNK Signal Transduction Pathway
Dickens, M., Rogers, J. S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J. R., Greenberg, M. E., Sawyers, C. L., & Davis, R. J. (1997) · Science · doi:10.1126/science.277.5326.693 · Cited by 675
A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
Borsello, T., Clarke, P. G. H., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., & Bonny, C. (2003) · Nature Medicine · doi:10.1038/nm911 · Cited by 658 · cited 2×
“It did not interfere with the activities of the other kinases [62, 63] proving its exceptional superiority.”
Self-citationA Mammalian Scaffold Complex That Selectively Mediates MAP Kinase Activation
Whitmarsh, A. J., Cavanagh, J., Tournier, C., Yasuda, J., & Davis, R. J. (1998) · Science · doi:10.1126/science.281.5383.1671 · Cited by 652 · cited 6×
“The specificity of JNK signaling is partially controlled by scaffold proteins [28].”
InfluentialCell-Permeable Peptide Inhibitors of JNK
Bonny, C., Oberson, A., Negri, S., Sauser, C., & Schorderet, D. F. (2001) · Diabetes · doi:10.2337/diabetes.50.1.77 · Cited by 571 · cited 2×
“Successively the JBD of JIP1 has been engineered as a cell permeable inhibitor peptide namely D-JNKI1 [59].”
The JIP Group of Mitogen-Activated Protein Kinase Scaffold Proteins
Yasuda, J., Whitmarsh, A. J., Cavanagh, J., Sharma, M., & Davis, R. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7245 · Cited by 458 · cited 1×
“JIP1 and 2 are very similar, they contain the SH3 and PTB domains and they can also hetero-dimerize under certain conditions [37].”
Nuclear Accumulation of NFAT4 Opposed by the JNK Signal Transduction Pathway
Chow, C.-W., Rincón, M., Cavanagh, J., Dickens, M., & Davis, R. J. (1997) · Science · doi:10.1126/science.278.5343.1638 · Cited by 357 · cited 1×
“The isoforms differ somewhat in their substrate specificity in vitro [2], although the details of this are still unclear, but they have much in common and can all phosphorylate members of the AP-1 group of transcription factors as well as many different targets, both nuclear and cytoplasmic [1, 3–10] summarized in Fig.”
Savage, M. J., Lin, Y.-G., Ciallella, J. R., Flood, D. G., & Scott, R. W. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03376.2002 · Cited by 291 · cited 2×
“Some reports subsequently confirmed that this phosphorylation, mediated by JNK3, regulates APP cleavage by inducing the amyloidogenic processing of the protein, while JNK inhibition by blocking APP phosphorylation is reducing the rate of amyloidogenic processing in favor of the non-amyloidogenic one in vitro further u…”
Kim, M. J., Futai, K., Jo, J., Hayashi, Y., Cho, K., & Sheng, M. (2007) · Neuron · doi:10.1016/j.neuron.2007.09.007 · Cited by 278 · cited 1×
“The isoforms differ somewhat in their substrate specificity in vitro [2], although the details of this are still unclear, but they have much in common and can all phosphorylate members of the AP-1 group of transcription factors as well as many different targets, both nuclear and cytoplasmic [1, 3–10] summarized in Fig.”
Requirement of the JIP1 scaffold protein for stress-induced JNK activation
Whitmarsh, A. J., Kuan, C.-Y., Kennedy, N. J., Kelkar, N., Haydar, T. F., Mordes, J. P., Appel, M., Rossini, A. A., Jones, S. N., Flavell, R. A., et al. (2001) · Genes & Development · doi:10.1101/gad.922801 · Cited by 238
Identification of the Critical Features of a Small Peptide Inhibitor of JNK Activity
Barr, R. K., Kendrick, T. S., & Bogoyevitch, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107565200 · Cited by 211 · cited 1×
“Of those the most studied ones are: TAT-c Jun peptide, TI-JIP, L-JNKI and D-JNKI1 [58–60].”
Harding, T. C., Xue, L., Bienemann, A., Haywood, D., Dickens, M., Tolkovsky, A. M., & Uney, J. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000815200 · Cited by 111
Cited by
JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships
Zeke, A., Misheva, M., Reményi, A., & Bogoyevitch, M. A. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00043-14 · Cited by 523
c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer’s Disease
Yarza, R., Vela, S., Solas, M., & Ramirez, M. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00321 · Cited by 410
Goebel-Goody, S. M., Baum, M., Paspalas, C. D., Fernandez, S. M., Carty, N. C., Kurup, P., & Lombroso, P. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003053 · Cited by 159
“Bult A, Zhao F, Dirkx R Jr, Raghunathan A, Solimena M, and Lombroso PJ (1997) STEP: a family of brain-enriched PTPs. Alternative splicing produces transmembrane, cytosolic and truncated isoforms.”
BackgroundMethodInfluentialHypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases
Zhao, Y., Kuca, K., Wu, W., Wang, X., Nepovimova, E., Musilek, K., & Wu, Q. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12370 · Cited by 79
Beydoun, T., Deloche, C., Perino, J., Kirwan, B.-A., Combette, J.-M., & Behar-Cohen, F. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2013.0247 · Cited by 39
Metadata
- Authors
- Antoniou, X., Falconi, M., Di Marino, D., & Borsello, T.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2011-05-30
- Volume
- 24
- Issue
- 4
- Pages
- 633-642
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2150794515
- Cited by
- 86
- References
- 13
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.